OpenAI unveils GPT-Rosalind to accelerate drug discovery for pharma giants
New purpose-built AI model targets faster R&D cycles and deeper scientific insights across life sciences
New purpose-built AI model targets faster R&D cycles and deeper scientific insights across life sciences
The collaboration will embed OpenAI’s advanced AI systems across Novo Nordisk’s global operations
The goal is to deliver greater value to customers, doctors, and the broader healthcare ecosystem
Sanofi will leverage this partnership to provide access to proprietary data to develop AI models
Subscribe To Our Newsletter & Stay Updated